Vevorisertib

N/A

Report date: 2023/03/20 14:51:25
NME

Base Information

Drug NameVevorisertib
Drug Alias NameARQ-751
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase AKT2 inhibitorsSerine/threonine-protein kinase AKT3 inhibitors
TargetsSerine/threonine-protein kinase AKT2Serine/threonine-protein kinase AKT3
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArqule IncDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArqule Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A